Biogen Pharmachem Industries Inc Stock Price Today (NSE: BIOGEN)
Fundamental Score
Biogen Pharmachem Industries Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biogen Pharmachem Industries Inc share price today is ₹0.53, up +1.92% on NSE/BSE as of 30 March 2026. Biogen Pharmachem Industries Inc (BIOGEN) is a Small-cap company in the Other Financial Services sector with a market capitalisation of ₹68.60 (Cr). The 52-week high for BIOGEN share price is ₹1.08 and the 52-week low is ₹0.50. At a P/E ratio of 39.88x, BIOGEN is currently trading above its industry average P/E of 30.94x. The company has a Return on Equity (ROE) of -0.39% and a debt-to-equity ratio of 0.00.
Biogen Pharmachem Industries Inc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Biogen Pharmachem Industries Inc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Biogen Pharmachem Inc Share Price: A Financial Analysis
The Other Financial Services sector is currently experiencing increased volatility driven by evolving regulatory landscapes and shifting investor sentiment towards specialized lending models. This analysis focuses on Biogen Pharmachem Inc share price, which currently stands at ₹0.6899999976158142. Understanding its valuation metrics, particularly its Price-to-Earnings (PE) ratio of 39.88 and Return on Capital Employed (ROCE) of -0.39%, is crucial for assessing its financial health within this dynamic environment. This assessment forms part of an extensive, 80-parameter fundamental audit verified by Sweta Mishra.
A PE ratio of 39.88 suggests that investors are willing to pay a relatively high price for each rupee of earnings. This could indicate expectations of future growth, but should be viewed cautiously in light of the company’s negative ROCE. The negative ROCE of -0.39% is a significant concern. It signifies that Biogen Pharmachem Inc. is not generating profits from its invested capital, which weakens its competitive advantage or moat. A strong ROCE is often indicative of efficiency and a solid economic moat, allowing a company to outperform its competitors.
Comparing Biogen Pharmachem Inc. to its peers reveals further insights. Consider
Sumedha Fiscal Services Ltd. While we cannot comment directly on management quality without deeper investigation, consistent profitability and higher ROCE in peer companies (if observed) might suggest different operational efficiencies and strategic decision-making processes. Further investigation into Biogen Pharmachem Inc.’s cost structure and revenue generation would be beneficial to determine the root causes of the negative ROCE and high PE ratio.In conclusion, the Biogen Pharmachem Inc share price should be viewed in the context of its high PE ratio and negative ROCE. The financial data suggests caution. Further investigation is warranted to understand the drivers of these metrics and the company's long-term sustainability within the Other Financial Services sector. This analysis is observational and does not constitute financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biogen Pharmachem Industries Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOGEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (51.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-0.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.39%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.26%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biogen Pharmachem Industries Inc Financial Statements
Comprehensive financial data for Biogen Pharmachem Industries Inc including income statement, balance sheet and cash flow
About BIOGEN (Biogen Pharmachem Industries Inc)
Biogen Pharmachem Industries Inc (BIOGEN) is an emerging entity operating within the multifaceted realm of Other Financial Services, strategically positioned to leverage opportunit...ies in the dynamic financial landscape. Although relatively new under its current moniker since rebranding in March 2021, BIOGEN is actively carving a niche for itself by focusing on a diverse portfolio of financial activities beyond conventional banking or insurance models. The company concentrates on specialized financial solutions, potentially encompassing areas like investment management, capital market advisory, or bespoke financial instruments tailored to specific client needs. Its core strategy emphasizes a client-centric approach, seeking to deliver value through innovative and adaptive financial strategies designed to thrive in evolving market conditions. Based in Rajkot, India, BIOGEN harnesses a deep understanding of local market dynamics while simultaneously seeking to establish a broader national and potentially international footprint. The company operates with a commitment to transparency and ethical conduct, building trust with stakeholders through diligent risk management practices and adherence to regulatory compliance. BIOGEN's leadership team brings a wealth of experience in financial markets, coupled with a forward-thinking vision that prioritizes sustainable growth and long-term value creation. By embracing technology and data-driven insights, BIOGEN aims to optimize its operational efficiency and deliver cutting-edge financial solutions that resonate with its target clientele. BIOGEN's strategic direction revolves around identifying and capitalizing on underserved segments within the financial ecosystem. This proactive approach enables the company to tailor its services to meet the unique requirements of its clients, fostering lasting partnerships and solidifying its position as a trusted financial service provider. As it continues to evolve, BIOGEN is dedicated to innovation, continually exploring new avenues to expand its service offerings and enhance its capabilities. The company prioritizes building a strong, resilient foundation that will support its long-term aspirations and enable it to navigate the complexities of the ever-changing financial landscape with confidence and agility.
Company Details
Key Leadership
Latest News
BIOGEN Share Price: Frequently Asked Questions
What is the current share price of Biogen Pharmachem Industries Inc (BIOGEN)?
As of 30 Mar 2026, 11:00 am IST, Biogen Pharmachem Industries Inc share price is ₹0.53. The BIOGEN stock has a market capitalisation of ₹68.60 (Cr) on NSE/BSE.
Is BIOGEN share price Overvalued or Undervalued?
BIOGEN share price is currently trading at a P/E ratio of 39.88x, compared to the industry average of 30.94x. Based on this relative valuation, the Biogen Pharmachem Industries Inc stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BIOGEN share price?
The 52-week high of BIOGEN share price is ₹1.08 and the 52-week low is ₹0.50. These values are updated daily from NSE/BSE price data.
What factors affect the Biogen Pharmachem Industries Inc share price?
Key factors influencing BIOGEN share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biogen Pharmachem Industries Inc a good stock for long-term investment?
Biogen Pharmachem Industries Inc shows a 5-year Profit Growth of N/A% and an ROE of -0.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in BIOGEN shares.
How does Biogen Pharmachem Industries Inc compare with its industry peers?
Biogen Pharmachem Industries Inc competes with major peers in the Other Financial Services. Investors should compare BIOGEN share price P/E of 39.88x and ROE of -0.39% against the industry averages to determine competitive standing.
What is the P/E ratio of BIOGEN and what does it mean?
BIOGEN share price has a P/E ratio of 39.88x compared to the industry average of 30.94x. Investors pay ₹40 for every ₹1 of annual earnings.
How is BIOGEN performing according to Bull Run's analysis?
BIOGEN has a Bull Run fundamental score of 13.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BIOGEN belong to?
BIOGEN operates in the Other Financial Services industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biogen Pharmachem Industries Inc share price.
What is Return on Equity (ROE) and why is it important for BIOGEN?
BIOGEN has an ROE of -0.39%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Biogen Pharmachem Industries Inc generates profits from shareholders capital.
How is BIOGEN debt-to-equity ratio and what does it indicate?
BIOGEN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is BIOGEN dividend yield and is it a good dividend stock?
BIOGEN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Biogen Pharmachem Industries Inc shares.
How has BIOGEN share price grown over the past 5 years?
BIOGEN has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BIOGEN and why does it matter?
Promoters hold 0.00% of BIOGEN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Biogen Pharmachem Industries Inc.
What is BIOGEN market capitalisation category?
BIOGEN has a market capitalisation of ₹69 crores, placing it in the Small-cap category.
How volatile is BIOGEN stock?
BIOGEN has a beta of N/A. A beta > 1 suggests the Biogen Pharmachem Industries Inc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BIOGEN operating profit margin trend?
BIOGEN has a 5-year average Operating Profit Margin (OPM) of 0.26%, indicating the company's operational efficiency.
How is BIOGEN quarterly performance?
Recent quarterly performance shows Biogen Pharmachem Industries Inc YoY Sales Growth of N/A% and YoY Profit Growth of 51.00%.
What is the institutional holding pattern in BIOGEN?
BIOGEN has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Biogen Pharmachem Industries Inc stock.